Patient and clinician preferences for biologic treatments for severe uncontrolled asthma: a discrete choice experiment (DCE)-Reference-Cited by-同舟云学术

Patient and clinician preferences for biologic treatments for severe uncontrolled asthma: a discrete choice experiment (DCE)

Published:2024-08 Issue: Volume: Page:1-13
ISSN:0277-0903
Container-title:Journal of Asthma
language:en
Short-container-title:Journal of Asthma

Author:

Ross Melissa M.¹^ORCID,Chung Yen²,Carr Tara³,Ambrose Christopher S.²,Lindsley Andrew W.⁴,Collacott Hannah¹,Schulz Andrea¹,Desai Pooja⁵,Rane Pallavi⁴,Williams Matthew⁶,Gelhorn Heather L.¹

Affiliation:

1. Evidera Inc., Wilmington, NC, USA

2. AstraZeneca, Wilmington, DE, USA

3. Asthma and Airways Disease Research Center, University of AZ, Tucson, AZ, USA

4. Amgen, Thousand Oaks, CA, USA

5. Novartis, East Hanover, NJ, USA

6. Northern VA Pulmonary and Critical Care Associates PC, Annadale, VA, USA

Funder

AstraZeneca

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/02770903.2024.2380520

Reference31 articles.

1. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention 2017. Available from: https://ginasthma.org/wp-content/uploads/2019/04/wmsGINA-2017-main-report-final_V2.pdf [last accessed 25 March 2021].

2. Center for Disease Control and Prevention (CDC). Most Recent National Asthma Data 2022. Available from: https://www.cdc.gov/asthma/most_recent_national_asthma_data.htm [last accessed 25 March 2022].

3. Severe Asthma in a General Population Study: Prevalence and Clinical Characteristics

4. Difficult-to-Treat & Severe Asthma in Adolescent and Adult Patients. Global Initiative for Asthma (GINA); 2023. Available from: https://ginasthma.org/wp-content/uploads/2023/09/GINA-Severe-Asthma-Guide-2023-WEB-WMS.pdf.

5. Trends and Disparities in Asthma Biologic Use in the United States